Cargando…
5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft
Somatic mutations in Isocitrate Dehydrogenase 1 (IDH1) are frequent in low grade and progressive gliomas and are characterized by the production of 2-hydroxyglutarate (2-HG) from α-ketoglutarate by the mutant enzyme. 2-HG is an “oncometabolite” that competitively inhibits α-KG dependent dioxygenases...
Autores principales: | Borodovsky, Alexandra, Salmasi, Vafi, Turcan, Sevin, Fabius, Armida W. M., Baia, Gilson S., Eberhart, Charles G., Weingart, Jon D., Gallia, Gary L., Baylin, Stephen B., Chan, Timothy A., Riggins, Gregory J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858560/ https://www.ncbi.nlm.nih.gov/pubmed/24077805 |
Ejemplares similares
-
Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine
por: Turcan, Sevin, et al.
Publicado: (2013) -
Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
por: Park, Jong-Whi, et al.
Publicado: (2019) -
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
por: Sun, Xueyuan, et al.
Publicado: (2021) -
Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas
por: Wang, Yuxiang, et al.
Publicado: (2020) -
Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas
por: Al-Ali, Ruslan, et al.
Publicado: (2019)